About Mitofam
Add Pedigree
Help
About Mitofam
Add Pedigree
Help
MT-TL2
A12280G
A12280G-F1
A12299C
A12299C-F1
A12308G
A12320G
A12320G-F1
G12276A
G12283A
G12293A
G12293A-F1
G12294A
G12300A
G12300A-F1
G12315A
G12316A
G12316A-F1
G12334A
T12278C
T12297C
T12297C-F4
T12297C-F3
T12297C-F1
T12311C
T12313C
T12313C-F1
T12317C
Edit by Mitofam Team
-
+
首页
G12294A
# **General Information** | **Position** | **12294** | **Variant** | **m.12294G\>A** | **Locus** | **MT\-TL2** | **RNA** | **tRNA Leu (CUN)** | | --- | --- | --- | --- | --- | --- | --- | --- | | **Homoplasmy** | \- | **Heteroplasmy** | \+ | **mitoTIP** | Pathogenic | **Pathogenicity** | Cfrm \[VUS\*] | "Pathogenicity" status is derived from published literature or predictions from bioinformatics tools. Researchers and clinicians are cautioned that additional data and/or analysis may still be necessary to confirm the pathological significance of these variants. For more information, please see [Mitofam Info](https://mitofam.com/doc/385/). # **Pedigree Information** The **m.12294G\>A** variant in MT\-TL2 has been reported in 2 pedigrees. To date, 2 carriers have been reported. Reported mutation loads ranged from 0% to 75%, with a median of 0% overall; affected carriers showed mutation loads from 0% to 75%, with a median of 0%. In one affected carrier, the mutation was undetectable in blood (0%) and myoblast culture (0%) but exceeded 20% in muscle (59\.8%). In one affected carrier, the mutation was undetectable in blood (0%), urine (0%), and bone marrow (0%) but exceeded 20% in muscle (75%). The main clinical manifestations among affected carriers included CPEO, pure exercise intolerance, exercise intolerance, mild limb weakness, and ophthalmoplegia. | **No.** | **Position** | **Variant** | **Family ID** | **Nationality** | **Diseases** | **Unaffected Maternal Relatives** | **Affected Maternal Relatives** | **Publication Year** | **PMID/Ref** | **Note** | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 12294 | m.12294G\>A | G12294A\-F1 | Thailand | CPEO, mild limb weakness, exercise intolerance | ND | ND | 2003 | [14581685](https://pubmed.ncbi.nlm.nih.gov/14581685/) | | | 2 | 12294 | m.12294G\>A | G12294A\-F2 | Denmark | Pure exercise intolerance, ophthalmoplegia | 0 | 0 | 2017 | [29052516](https://pubmed.ncbi.nlm.nih.gov/29052516/) | | # **Carrier Information** | **No.** | **Position** | **Variant** | **Family ID** | **Carrier ID** | **Type (Fam/De novo/Uninf)** | **Gender (F/M)** | **Proband (Y/N)** | **Affected (Y/N)** | **Die/Alive(D/A)** | **Age** | **Blood Mutant Level** | **Muscle Mutant level** | **Urine Mutant level** | **Other Mutant level** | **Clinical Features** | **Note** | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 12294 | m.12294G\>A | G12294A\-F1 | G12294A\-F1\-P1 | Uninf | F | Y | Y | A | 44 | 0 | 59\.8% | / | 0% (Myoblast culture) | CPEO, mild limb weakness, exercise intolerance | | | 2 | 12294 | m.12294G\>A | G12294A\-F2 | G12294A\-F2\-P1 | De novo | M | Y | Y | A | 39 | 0 | 75% | 0 | 0% (BM) | Pure exercise intolerance, ophthalmoplegia | | For abbreviations and other usage instructions, please see [Mitofam Info](https://mitofam.com/doc/385/).
Haoying Chen
2026年6月25日 14:20
转发
收藏文档
上一篇
下一篇
手机扫码
复制链接
手机扫一扫转发分享
复制链接
分享
链接
类型
密码
更新密码
有效期
Markdown文件
Word文件
PDF文档
PDF文档(打印)